Aptevo CMO settles 638 RSUs into common stock

Aptevo Therapeutics Inc. officer Dirk Huebner (SVP, CMO) reported the vesting and settlement of 638 Restricted Stock Units (RSUs) into 638 shares of common stock on August 6, 2026.

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. officer Dirk Huebner (SVP, CMO) reported the vesting and settlement of 638 Restricted Stock Units (RSUs) into 638 shares of common stock on August 6, 2026. The RSUs, originally granted on August 6, 2025, converted to common stock on a one-for-one basis. In a related transaction, 156 shares of common stock were withheld by the issuer at $4.07 per share to satisfy tax withholding obligations on the RSU vesting.

Insider Trade Summary

638 shares exercised/converted

Exercise 3 txns

Insider Huebner Dirk

Role SVP, CMO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F3	638	$0.00	$0.00
Exercise	Common Stock F1	638	--	--
Tax Withholding	Common Stock F2	156	$4.07	$634.92

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 482 shares (Direct)

Footnotes (3)

1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. F2. Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
3. F3. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

Key Figures

RSUs converted: 638 RSUs Common shares issued from RSUs: 638 shares Shares withheld for taxes: 156 shares at $4.07 per share +1 more

4 metrics

RSUs converted 638 RSUs Restricted Stock Units converting into common stock on August 6, 2026

Common shares issued from RSUs 638 shares Shares of common stock received upon RSU conversion

Shares withheld for taxes 156 shares at $4.07 per share Common stock withheld to satisfy tax withholding obligations on RSU vesting

Original RSU grant size (pre-split) 11,500 RSUs (638 post-split) Grant to Dirk Huebner on August 6, 2025 vesting on first anniversary

Key Terms

Restricted Stock Unit, tax withholding obligations, par value

3 terms

Restricted Stock Unit financial

"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax withholding obligations financial

"Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting"

par value financial

"common stock, $0.001 par value per share, of the Issuer on a one-for-one basis"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did APVO officer Dirk Huebner report on August 6, 2026?

Dirk Huebner reported the vesting and settlement of 638 RSUs into 638 shares of Aptevo Therapeutics (APVO) common stock, reflecting an exercise/conversion of previously granted equity compensation.

How many Aptevo Therapeutics (APVO) shares were withheld for taxes in this Form 4?

The filing shows that 156 shares of Aptevo Therapeutics common stock were withheld by the issuer at $4.07 per share to satisfy tax withholding obligations related to the RSU vesting.

What equity award originally led to the reported RSU vesting at APVO?

The RSUs vesting on August 6, 2026 came from an award granted on August 6, 2025 of 11,500 RSUs (638 post-split), which were structured to vest on the first anniversary of the grant date.

Did the APVO Form 4 report an open-market buy or sell by Dirk Huebner?

No open-market buy or sell is reported. The Form 4 reflects an RSU conversion into common stock and shares withheld to cover tax obligations, rather than discretionary market purchases or sales.

What types of securities were involved in Dirk Huebner’s APVO Form 4 filing?

The filing involves Restricted Stock Units (RSUs), which converted into common stock, and a separate transaction where common shares were withheld by Aptevo Therapeutics to satisfy tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 09:35 PM Accepted by SEC EDGAR 08/10/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huebner Dirk

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		638	A	(1)	638	D
Common Stock	08/06/2026		F(2)		156	D	$4.07	482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2026		M			638	(3)	(3)	Common Stock	638	$0	0	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.

3. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)